SB 1768 Opens Door to Non-FDA-Approved Stem Cell Therapies: What Patients Need to Know
Are you wondering what SB 1768 means for your access to stem cell treatments? Have you heard about new state laws allowing non-FDA-approved therapies? Do you want to understand how these changes might affect your treatment options for orthopedic conditions, wound care, or chronic pain? These questions reflect growing interest in recent state legislation that […]
Nation’s First Regenerative Medicine Program: UB & TulsiHub Lead the Way
University of Bridgeport and TulsiHub Institute are partnering to launch a unique regenerative medicine certificate program, reportedly the first of its kind nationally. This 12-week program is designed to provide healthcare professionals and students with advanced skills in areas like stem cell therapy and tissue engineering. Graduates will be eligible for seed funding to establish their own clinics, helping to meet the growing demand in the rapidly […]
DNA’s Hidden Helpers: How They Control Stem Cells for Healing
A study led by UC Riverside explored how adult stem cells maintain their ability to renew, a process critical for tissue repair and regeneration. Researchers discovered that helper proteins called histone chaperones are essential for properly organizing DNA and ensuring stem cells remain in their undifferentiated state. When these chaperones are disrupted, the stem cells lose their renewal capacity and begin […]
Stem Cell Therapy Breakthrough: CIBA Method Offers New Hope for Critically Ill Lung Patients
A recent study published in Stem Cell Research & Therapy introduces a novel method for delivering stem cell therapy to patients with severe lung conditions who are supported by extracorporeal membrane oxygenation (ECMO). Understanding the Challenge Patients with end-stage interstitial lung disease (ILD) often rely on ECMO when traditional treatments fail. However, administering stem cells […]
FDA Grants Orphan Drug Designation to Cell Therapy CK0801 for Rare Aplastic Anemia
Cellenkos, Inc. announced that its CK0801, an allogeneic T regulatory cell therapy derived from cord blood, has received Orphan Drug Designation from the FDA for the treatment of aplastic anemia, a rare bone marrow disorder. This designation provides Cellenkos with incentives to further develop CK0801, which has shown promising Phase 1 clinical trial results, including durable transfusion independence in some patients who did not […]
The Future of Stem Cell Transplantation: Insights from Dr. Kevin McNerney
In an era where medical science is rapidly transforming lives, stem cell transplantation stands at the forefront of innovative treatment. At the Bone Marrow Transplant and Gene Therapy Congress in Abu Dhabi, Dr. Kevin McNerney from the Ann & Robert H. Lurie Children’s Hospital in Chicago shares groundbreaking updates and real-world insights into this life-saving […]
Stem Cell Breakthrough: Ryoncil® and the Fight Against a Deadly Childhood Disease
Mesoblast, a leader in cell-based therapies, announced that its product Ryoncil® received coverage from the Centers for Medicare and Medicaid Services (CMS). This agreement ensures access to this newly FDA-approved mesenchymal stromal cell therapy for children with steroid-refractory acute graft versus host disease (SR-aGvHD) covered by Medicaid. Consequently, the first three pediatric patients will begin receiving Ryoncil® treatment this […]
Stem Cell Therapy: A Game-Changer for Brain Injury Recovery
Concussions and brain injuries have long plagued athletes, accident victims, and everyday individuals, often resulting in long-term disabilities and diminished quality of life. However, a promising new treatment—stem cell therapy—may offer a revolutionary path to recovery. One recent case sheds light on the potential of this therapy to restore hope and function for those suffering […]
Sernova FDA Clearance: Cell Pouch for Hypothyroidism Treatment
Sernova Biotherapeutics has received FDA clearance for its Investigational New Drug (IND) application. This clearance allows them to evaluate their Cell Pouch bio-hybrid organ, combined with autograft thyroid cells, in patients with hypothyroidism undergoing thyroid surgery. The Cell Pouch aims to restore natural thyroid function, eliminating the need for hormone replacement therapy. Preclinical studies showed […]
Celularity and BlueSphere Bio Collaborate on Cell Therapy Manufacturing
Celularity Inc., a cellular medicine company, has entered into a collaboration agreement with BlueSphere Bio (BSB).? Celularity will leverage its manufacturing capabilities to produce BSB’s T cell receptor (TCR) T cell therapies.? This partnership will focus on manufacturing and quality control at Celularity’s New Jersey facility for BSB’s therapies, including a treatment for Acute Myelogenous […]